Aurobindo Pharma Ltd.

•

aurobindo.comBSE: 524804NSE: AUROPHARMA

Market Cap₹ 96,402 Cr.

Current Price

High / Low₹ 1,717 / 1,067

Stock P/E26.0

Book Value₹ 676

Price to Book2.00

Dividend Yield0.24 %

ROCE12.8 %

ROE9.9 %

Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has consistently been profitable over the last 5 years
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.17x)
Latest quarter profit grew 25.2% YoY, showing strong momentum
Company comfortably covers its interest (14.3x coverage)
Company generates healthy free cash flow
Company maintains a comfortable, low leverage position

CONS

Receivables are growing faster than sales - a possible quality concern
Company has delivered a poor profit growth of -8.1% over past five years
Recurring exceptional / one-off items are inflating headline profit
Company has delivered a poor sales growth of 6.3% over past five years
Though reporting repeated profits, the company pays out little dividend (6.6%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTYM150MOMNTM50 NIFTY PHARMA NIFTYLARGEMIDCAP250 NIFTYMIDCAP150 NIFTY MIDCAP 100

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	BIOCON	390.95	128.63	63712.89	0.13	136.80	53.36	4336.00	10.89	3.26	19.54

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	6,791	7,151	7,271	7,492	7,458	7,646	7,893	8,381	7,792	8,237	8,605	8,752	9,150
	5,699	5,846	5,750	5,907	5,947	6,230	6,401	6,590	6,265	6,608	6,873	7,101	7,858
Operating Profit	1,091	1,305	1,521	1,585	1,510	1,416	1,493	1,791	1,527	1,629	1,732	1,651	1,293
OPM %	16.07%	18.25%	20.91%	21.15%	20.25%	18.52%	18.91%	21.37%	19.59%	19.78%	20.13%	18.86%	14.13%
	47	187	163	14	221	136	157	135	105	121	122	117	304
Interest	57	68	76	89	111	113	118	115	98	95	93	98	102
Depreciation	327	418	423	354	404	382	419	444	406	429	465	479	487
Profit before Tax	815	1,075	1,265	1,243	1,325	1,207	1,198	1,367	1,205	1,274	1,338	1,293	1,515
Tax %	29.74%	30.12%	25.49%	25.96%	30.61%	32.35%	29.57%	31.61%	31.75%	33.57%	32.04%	28.60%	31.88%
Net Profit	0	0	0	0	918	817	846	903	824	848	910	921	1,032
	9.74	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	14,910	16,463	19,564	23,099	24,775	23,455	24,855	29,002	31,724	33,653	34,743
	11,475	12,691	15,612	18,234	19,441	19,071	21,137	23,159	25,141	26,836	28,438
Operating Profit	3,434	3,772	3,952	4,864	5,333	4,385	3,719	5,843	6,583	6,817	6,305
OPM %	23.03%	22.91%	20.20%	21.06%	21.53%	18.69%	14.96%	20.15%	20.75%	20.26%	18.15%
	116	102	67	166	3,195	195	291	366	622	455	664
Interest	67	78	263	305	74	49	140	290	457	384	388
Depreciation	428	558	668	967	1,055	1,127	1,245	1,522	1,649	1,778	1,859
Profit before Tax	3,061	3,241	3,091	3,743	7,344	3,373	2,612	4,380	5,066	5,112	5,421
Tax %	24.82%	25.25%	23.51%	24.03%	27.37%	21.51%	26.21%	27.65%	31.24%	31.47%	31.53%
Net Profit	2,301	2,423	2,364	2,844	5,334	2,647	1,928	3,169	3,484	3,503	3,711
EPS	39.33	41.36	40.36	48.56	91.05	45.19	32.90	54.16	60.02	60.34	—
Dividend Payout %	6.36%	6.04%	6.19%	6.18%	4.39%	19.91%	9.12%	8.31%	0.00%	6.63%	—

COMPOUNDED SALES GROWTH

10 Years:: 9%
5 Years:: 6%
3 Years:: 11%

COMPOUNDED PROFIT GROWTH

10 Years:: 6%
5 Years:: -8%
3 Years:: 22%

STOCK PRICE CAGR

10 Years:: 8%
5 Years:: 18%
3 Years:: 24%
1 Year:: 51%

RETURN ON EQUITY

10 Years:: 17%
5 Years:: 10%
3 Years:: 11%
Last Year:: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	59	59	59	59	59	59	59	59	58	58
Minority Interest	2	2	2	0	-1	-2	12	8	-6	-8
	9,313	11,622	13,832	16,766	21,871	24,517	26,781	29,784	32,595	37,833
	3,273	4,781	6,787	5,774	5,332	2,727	5,212	6,517	7,340	7,954
Trade Payables	2,155	2,373	2,552	2,576	2,795	2,703	3,871	4,454	4,189	5,567
	1,280	2,107	3,040	3,589	3,346	3,629	3,277	3,036	4,317	5,615
Total Liabilities	16,082	20,942	26,271	28,765	33,401	33,633	39,212	43,859	48,492	57,019
	4,834	6,521	8,475	9,396	9,374	10,532	11,024	14,493	14,794	17,407
Capital Work in Progress	1,237	1,400	1,342	1,622	2,429	2,938	4,496	2,739	3,266	3,009
	246	312	360	555	591	997	543	372	252	1,051
	4,331	5,858	7,246	7,700	9,027	7,554	8,511	9,808	10,544	12,053
	0	15	16	0	27	16	25	4,817	5,746	7,094
Cash & Bank	513	1,262	1,957	2,842	5,474	4,190	6,084	6,278	8,235	9,870
	4,921	5,575	6,875	6,650	6,480	7,407	8,529	5,351	5,655	6,534
Total Assets	16,082	20,942	26,271	28,765	33,401	33,633	39,212	43,859	48,492	57,019

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4,052	2,653	2,421	5,142	4,614	6,275	3,104	2,435	3,925	5,526
Cash from Investing	-1,787	-1,927	-2,903	-1,568	599	-3,212	-3,978	-4,256	-1,876	-3,459
Cash from Financing	-1,915	864	1,919	-1,947	-1,365	-2,969	1,814	800	120	-1,269
	-424	892	667	866	2,563	-1,164	223	-1,021	2,169	799

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	51.80	51.82	51.82	51.82	51.82	51.82	51.82	51.82	51.88
	16.73	16.59	16.29	15.33	14.38	14.21	13.95	15.24	16.38
	24.77	25.14	25.21	26.23	26.93	27.60	27.66	25.82	25.05
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	6.70	6.46	6.69	6.61	6.87	6.38	6.56	7.08	6.64

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-12

Acquisition

2026-09-12 - Aurobindo Pharma Limited has informed the Exchange about Acquisition

2026-09-11

General Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company

2026-09-11

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-03

Copy of Newspaper Publication

2026-09-03 - Aurobindo Pharma Limited has submitted copy of Newspaper Publications.

2026-09-01

Acquisition

2026-09-01 - AUROPHARMA: Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned subsidiary by the name of Avogent Lifesciences Private Limited in India by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

News

Recent coverage and analyst commentary for AUROPHARMA

Loading news…

🤖

AI Stock Analyst

Aurobindo Pharma Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account